Sevan Announces Appointment of Two New Board Members
22.7.2020 16:00:00 EEST | Business Wire | Press release
Sevan Multi-Site Solutions, Inc. (Sevan) — a global leader in innovative design, program management, construction services and data analytics — announced the appointment of two new board members to the company’s Board of Directors.
Joining the board are Jim Blayney and Frank McGrew. Both bring decades of leadership in strategy, growth (including mergers and acquisitions), sales, marketing, finance and operations.
“We welcome Jim and Frank to Sevan’s board and look forward to their valuable counsel, expertise and unique perspectives,” said Jim Evans, President and CEO of Sevan. “Their knowledge and guidance will strengthen Sevan’s commitment to deliver excellence to our clients, business partners, employees and shareholders.”
Blayney currently serves on the Board of Directors of Steffes, LLC and Viventium. He also serves on the Board of Advisors of CBE Companies, Inc. and EVS, Inc. He guides these businesses on strategy, growth opportunities and general business best practices. Blayney has more than 35 years of experience and has served as President and CEO of numerous corporations including Renew Data Corporation, Rust Consulting, Inc. and the Legal and Claims Division of Sourcecorp, Inc. He has served as a board member and advisor for many companies. Blayney has a Master of Science in Accounting from University of Wisconsin, a Bachelor of Arts in Economics from Central College in Pella, Iowa and was a CPA.
McGrew most recently was Managing Partner at McNally Capital, LLC responsible for establishing strategy, initiating new business and providing execution oversight for the firm’s merchant banking operations while also supporting direct investing activity. He has more than 30 years of experience related to investment banking, mergers and acquisitions, corporate finance and investing. McGrew has an MBA from the Wharton School of the University of Pennsylvania and a Bachelor of Business Administration in Finance from Southern Methodist University’s Cox School of Business.
Other members of Sevan’s six-person board include Jim Evans – Majority Owner and CEO of Sevan, Phil Clough – Managing General Partner at ABS Capital Partners, Steve Kuhn – Executive Vice President at Sevan, and Chris Souther – Chief Financial Officer at Griffis Residential. Evans, Kuhn and Souther have all been board members since Sevan was founded in 2011. Clough has had a seat on the board since December 2019 when ABS Capital Partners became a minority investor in Sevan.
Founded in 2011, Sevan helps clients develop, refresh and update their portfolio of sites. Large public competitors are not typically focused on the multi-site market, and smaller companies are often unable to compete with the breadth and quality of services Sevan provides.
In 2020, Sevan was recognized as an Employee-Rated Great Place to Work® for the 7th consecutive year and ranked No. 124 on the Financial Times FT 1000 list of America’s Fastest-Growing Companies. In 2019, Sevan ranked No. 713 on the Inc. 5000 list of the nation’s fastest-growing private companies. In 2018, Great Place to Work® and FORTUNE ranked Sevan No. 29 on the list of 100 Best Medium Workplaces. A full list of awards and rankings Sevan has earned to date is available on Sevan’s website.
Sevan is a project management firm headquartered in Downers Grove, IL, with 400+ employees and an international office in London.
About Sevan
The vision of Sevan Multi-Site Solutions is to be the best in the world at delivering innovative design, program management, construction services and data analytics to organizations with multiple sites. Sevan has a passion for sustaining people, the environment and its clients’ businesses. Sevan helps iconic global brands, including 7-Eleven, AAFES, Albertsons, Amtrak, BP, Chipotle, DaVita, HCA Healthcare, Hallmark, HEB, Jiffy Lube, Kroger, Marathon, McDonald’s, Office Depot, Starbucks, Sunoco, Walgreens Boots Alliance, Walmart and Zaxby’s. Sevan rolls out multi-site initiatives efficiently, predictably and transparently. Applying breakthrough technology solutions, Sevan optimizes new builds, rebuilds, remodels and renovations. Sevan surveys more than 150 million square feet annually and has licensed architects in 49 states as well as D.C., Canadian provinces, Guam, and the Northern Mariana Islands. Sevan has professional engineers on staff and general contractor licenses in more than 25 states. Since Sevan’s inception in 2011, the team has refreshed more than 21,000 retail stores and 14,000 restaurants. To read more about Sevan, visit www.sevansolutions.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200722005312/en/
Contact information
Hafsa Mahmood
Manager, Marketing & Communications
Phone: 312.285.0590
E-mail:
hafsa.mahmood@sevansolutions.com
Website:
www.sevansolutions.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
